### **INM-7: Brain and Behaviour**






Individualized assessment of resting state spatial activation patterns as a biomarker for Parkinson's disease

Juergen Dukart

28.11.2019


### Ideally neuroimaging provides a link between biology and behaviour





Generally rather low to fair reliability of region- and voxel-wise

fMRI and rsfMRI analyses

#### Exemplary atlas region: ICC(reliability)=0.31







MID: Monetary Incentive Delay

ToM: Theory of Mind

FM: Emotional Face Matching


(f)ALFF: (fractional) Amplitude of low frequency fluctuations

ReHo: Regional Homogeneity

DC: Degree centrality
EC: Eigenvector centrality
CBF: Cerebral Blood Flow

### Within region reliability is rather moderate for most functional MRI measures

#### **fALFF** for 1 region (local activity)



MID: Monetary Incentive Delay

ToM: Theory of Mind

FM: Emotional Face Matching

(f)ALFF: (fractional) Amplitude of low frequency fluctuations

ReHo: Regional Homogeneity

DC: Degree centrality EC: Eigenvector centrality CBF: Cerebral Blood Flow

		median [P <sub>5</sub> -P <sub>95</sub> ]
		Between ICC
tb- fMRI	MID	0.70 [-0.00-0.88]
	N-back	0.38 [-0.09-0.68]
	ToM	0.42 [-0.09-0.69]
	FM	0.38 [-0.15-0.71]
	Encoding	0.30 [-0.19-0.58]
	Recall	0.23 [-0.84-0.77]
	Recognition	0.48 [0.03-0.72]
	Go/no-go	-0.16 [-0.74-0.36]
rs-fMRI	ALFF	0.72 [0.27-0.86]
	fALFF	0.57 [0.17-0.75]
	ReHo	0.58 [0.21–0.78]
	DC	0.44 [-0.04-0.71]
	EC	0.36 [-0.15-0.67]
	Hurst	0.45 [0.18-0.64]
ASL	CBF	0.83 [0.42-0.91]

Visit 1 to visit 2


ICC criteria (Cicchetti, Domenic V. 1994). Less than 0.40—poor. Between 0.40 and 0.59—fair. Between 0.60 and 0.74—good. Between 0.75 and 1.00—excellent.

ICC - Intra-class correlation coefficient

Holiga et al., 2018, Plos One

Spatial reliability across regions is consistently higher than the reliability within each region for task-based fMRI and rsfMRI





Time point 1

MID: Monetary Incentive Delay

ToM: Theory of Mind

FM: Emotional Face Matching

(f)ALFF: (fractional) Amplitude of low frequency fluctuations

ReHo: Regional Homogeneity

DC: Degree centrality
EC: Eigenvector centrality
CBF: Cerebral Blood Flow

	median $[P_5-P_{95}]$	median $[P_5-P_{95}]$
	Between ICC	Within ICC
MID	0.70 [-0.00-0.88]	0.79 [-0.32-0.93]
N-back	0.38 [-0.09-0.68]	0.81 [0.61–0.94]
ToM	0.42 [-0.09-0.69]	0.58 [-0.10-0.83]
FM	0.38 [-0.15-0.71]	0.80 [0.63-0.93]
Encoding	0.30 [-0.19-0.58]	0.73 [0.47-0.94]
Recall	0.23 [-0.84-0.77]	0.72 [0.25-0.89]
Recognition	0.48 [0.03-0.72]	0.72 [0.48-0.86]
Go/no-go	-0.16 [-0.74-0.36]	0.24 [-1.11-0.66]
ALFF	0.72 [0.27–0.86]	0.96 [0.73-0.98]
fALFF	0.57 [0.17-0.75]	0.98 [0.95-0.99]
ReHo	0.58 [0.21-0.78]	0.96 [0.86-0.98]
DC	0.44 [-0.04-0.71]	0.89 [0.62-0.95]
EC	0.36 [-0.15-0.67]	0.65 [0.19-0.92]
Hurst	0.45 [0.18-0.64]	0.92 [0.77-0.96]
CBF	0.83 [0.42-0.91]	0.96 [0.91-0.98]
	N-back ToM FM Encoding Recall Recognition Go/no-go ALFF fALFF ReHo DC EC Hurst	MID         0.70 [-0.0] 0-0.88]           N-back         0.38 [-0.0] 9-0.68]           ToM         0.42 [-0.0] 9-0.69]           FM         0.38 [-0.1] 5-0.71]           Encoding         0.30 [-0.1] 9-0.58]           Recall         0.23 [-0.8] 4-0.77]           Recognition         0.48 [0.0] 3-0.72]           Go/no-go         -0.16 [-0.7] 4-0.36]           ALFF         0.57 [0.1] 7-0.75]           ReHo         0.58 [0.2] 1-0.78]           DC         0.44 [-0.0] 4-0.71]           EC         0.36 [-0.1] 5-0.67]           Hurst         0.45 [0.1] 8-0.64]

ICC criteria (Cicchetti, Domenic V. 1994):

Less than 0.40—poor.

Between 0.40 and 0.59—fair.

Between 0.60 and 0.74—good.

Between 0.75 and 1.00—excellent.


ICC - Intra-class correlation coefficient

Holiga et al., 2018, Plos One

# Pharmacodynamic mapping of drug receptor profiles using Cerebral Blood Flow – Illustration of the concept

Correlating spatial profiles of receptor densities and drug/disease effects


Receptor density



Correlations

# Spatial patterns of resting state regional activity are predictive of the underlying mechanism of action of respective compounds


Correlations with in vivo receptor density estimates (dopaminegic compounds)



### Study design – applying the spatial correlation approach to Parkinson's patients resting state fMRI data


Group	PD patients	Healthy controls
N	30	30
Age (mean±SD [range])	64.6±7.7	63.5±7.9
	[46-82]	[46-83]
sex (male/female)	13/17	15/15
UPDRS total off	45.3±15.0	-
(mean±SD [range])	[11-95]	
UPDRS total on	23.9±10.6	-
(mean±SD [range])	[5-47]	
UPDRS I off (mean±SD	1.6±1.7	-
[range])	[0-7]	
UPDRS I on (mean±SD	1.5±1.7	-
[range])	[0-7]	
UPDRS II off (mean±SD	13.1±6.4	-
[range])	[3-31]	
UPDRS II on (mean±SD	7.7±4.8	-
[range])	[0-17]	
UPDRS III off (mean±SD	30.6±9.9	-
[range])	[8-64]	
UPDRS III on (mean±SD	14.7±7.5	-
[range])	[4-31]	

Resting state BOLD



Fractional Amplitude of Low Frequency fluctuations (fALFF)







PD patients scanned on and off levodopa

### Statistical analyses

1. 2.




Voxel-wise group comparisons of fALFF maps




# Results – significant differences in spatial correlation but not in voxel-wise analyses


1. No significant differences between PD and HC in voxel-wise group comparisons










#### **Results**










# JuSpace: A tool for spatial correlation analyses of functional and structural neuroimaging data with positron emission tomography derived receptor maps



Available maps	Description
5HT1a	Serotonin system
5HT1b	Serotonin system
5HT2a	Serotonin system
AMYLOID	Alzheimer's pathology
CBF	Resting state activity in healthy
D1	Dopamine system
D2	Dopamine system
DAT	Dopamine system
FDOPA	Dopamine system
GABAa	GABA system
NAT	Noradrenaline
SERT	Serotonin system
TAU	Alzheimer's pathology

### **Key features**

- Allows for cross-modal correlation (Pearson/Spearman/multiple linear regression) of PET and (rs-f)MRI data
- Supports within and between subject designs
- Group- and individual subject level data

#### **Conclusions**

- PD patients show distinct spatial patterns of resting state alterations that match the distribution of several neurotransmitter systems (including dopamine and serotonin)
- The JuSpace tool provides the possibility to link individual subject and group level data to underlying receptor maps
- The proposed spatial correlation approach provides results that are better interpretable in terms of underlying biology
- Substantially increases the reliability of rs/fMRI analyses as compared to "classical" voxel- or region-based approaches



### THANK YOU FOR YOUR ATTENTION!

